World Workshop on Oral Medicine VII: Oral adverse effects to biologic agents in patients with inflammatory disorders. A scoping review.
biologic therapy
inflammatory disorders
oral adverse effects
scoping review
side effects
Journal
Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
ISSN: 1600-0714
Titre abrégé: J Oral Pathol Med
Pays: Denmark
ID NLM: 8911934
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
revised:
14
11
2022
received:
12
07
2022
accepted:
18
11
2022
pubmed:
2
12
2022
medline:
10
1
2023
entrez:
1
12
2022
Statut:
ppublish
Résumé
Biologic agents are rapidly emerging as an effective therapy to treat autoimmune and other chronic diseases. The use of these agents is poorly characterized, resulting in a lack of guidance for dental practitioners. Case reports of oral adverse events have begun to emerge. However, their scope and frequency have not been summarized and analysed to date. The objective of this review was to characterize the literature on oral adverse effects associated with biological therapy when used for autoimmune and inflammatory disorders. This review was developed in accordance with scoping review recommendations. Search strategies were developed and employed for six databases. Studies were selected using a systematic search process but with broad inclusion of study types given the paucity of information available. Reports of oral adverse events were analysed descriptively according to agent, mechanism of action, underlying disease, and oral adverse effect observed. Our search returned 2080 articles and 51 met our inclusion criteria, of which most were case reports. The most frequent adverse effects included angioedema, oral lichenoid lesions, osteonecrosis of the jaw, and oral infections. There were also cases of oral malignancies associated with use of biologic agents. Less common effects such as pigmentation were also described. Oral adverse events have been reported in patients on biologic therapy, albeit in small numbers to date. This limits the generalizability of these results, which should not be used to generate a clinical guideline as they are based primarily on case reports. However, this study presents the first review characterizing the adverse effects observed. Large multi-center studies will be necessary to further define the oral and dental complications caused by biologic agents.
Sections du résumé
BACKGROUND
BACKGROUND
Biologic agents are rapidly emerging as an effective therapy to treat autoimmune and other chronic diseases. The use of these agents is poorly characterized, resulting in a lack of guidance for dental practitioners. Case reports of oral adverse events have begun to emerge. However, their scope and frequency have not been summarized and analysed to date. The objective of this review was to characterize the literature on oral adverse effects associated with biological therapy when used for autoimmune and inflammatory disorders.
METHODS
METHODS
This review was developed in accordance with scoping review recommendations. Search strategies were developed and employed for six databases. Studies were selected using a systematic search process but with broad inclusion of study types given the paucity of information available. Reports of oral adverse events were analysed descriptively according to agent, mechanism of action, underlying disease, and oral adverse effect observed.
RESULTS
RESULTS
Our search returned 2080 articles and 51 met our inclusion criteria, of which most were case reports. The most frequent adverse effects included angioedema, oral lichenoid lesions, osteonecrosis of the jaw, and oral infections. There were also cases of oral malignancies associated with use of biologic agents. Less common effects such as pigmentation were also described.
CONCLUSIONS
CONCLUSIONS
Oral adverse events have been reported in patients on biologic therapy, albeit in small numbers to date. This limits the generalizability of these results, which should not be used to generate a clinical guideline as they are based primarily on case reports. However, this study presents the first review characterizing the adverse effects observed. Large multi-center studies will be necessary to further define the oral and dental complications caused by biologic agents.
Substances chimiques
Biological Factors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-8Informations de copyright
© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Patel SV, Khan DA. Adverse reactions to biologic therapy. Immunol Allergy Clin North Am. 2017;37(2):397-412.
O'Neill ID. Off-label use of biologicals in the management of inflammatory oral mucosal disease. J Oral Pathol Med. 2008;37(10):575-581.
Mays JW, Carey BP, Posey R, et al. World workshop of Oral medicine VII: a systematic review of immunobiologic therapy for oral manifestations of pemphigoid and pemphigus. Oral Dis. 2019;25(Suppl 1):111-121.
Gueiros LA, France K, Posey R, et al. World Workshop on Oral Medicine VII: immunobiologics for salivary gland disease in Sjögren's syndrome: a systematic review. Oral Dis. 2019;25(Suppl 1):102-110.
O'Neill ID, Scully C. Biologics in oral medicine: principles of use and practical considerations. Oral Dis. 2012;18(6):525-536.
O'Neill ID, Scully C. Biologics in oral medicine: oral Crohn's disease and orofacial granulomatosis. Oral Dis. 2012;18(7):633-638.
O'Neill ID, Scully C. Biologics in oral medicine: ulcerative disorders. Oral Dis. 2013;19(1):37-45.
Raychaudhuri SP, Raychaudhuri SK. Biologics: target-specific treatment of systemic and cutaneous autoimmune diseases. Indian J Dermatol. 2009;54(2):100-109.
Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011;2011(2):CD008794.
Kanwar N, Bakr M, Meer M, Siddiqi A. Emerging therapies with potential risks of medicine-related osteonecrosis of the jaw: a review of the literature. Br Dent J. 2020;228:886-892.
Eguia A, Bagán-Debón L, Cardona F. Review and update on drugs related to the development of osteonecrosis of the jaw. Med Oral Patol Oral Cir Bucal. 2020;25(1):e71-e83.
Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American Association of Oral and Maxillofacial Surgeons' position paper on medication-related osteonecrosis of the jaws-2022 update. J Oral Maxilofac Surg. 2022;80(5):920-943.
Yuan A, Woo SB. Adverse drug events in the oral cavity. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015;119(1):35-47.
The Joanna Briggs Institute. Joanna Briggs Institute Reviewers' Manual. 2017th ed. The Joanna Briggs Institute; 2017.
Peters MD, Godfrey CM, Khalil H, et al. Guidance for conducting systematic scoping reviews. JBI Evid Implement. 2015;13(3):141-146.
Munn Z, Peters MDJ, Stern C, Tufanaru C, McArthur A, Aromataris E. Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach. BMC Med Res Methodol. 2018;18(1):143.
Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation of the PRISMA-ScR statement. Ann Intern Med. 2018;169(7):467-473.
National Cancer Institute, National Institutes of Health. Cancer Dictionary. Accessed April 28, 2022. https://www.cancer.gov/publications/dictionaries/cancer-terms
Kellermeyer L, Harnke B, Knight S. Covidence and Rayyan. J Med Libr Assoc. 2018;106(4):580-583.
Somerfield MR, Padberg J, Pfister D. ASCO clinical practice Gudelines: process, progress, pitfalls, and prospects. Classic Pap Curr Commun. 2000;4(4):881-886.
Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-245.
Hansel K, Bianchi L, Tramontana M, et al. Immediate local and systemic hypersensitivity due to etanercept and adalumumab. J Allergy Clin Immunol Pract. 2019;7(2):726-727.
Magen E, Chikovani T. Development of angio-oedema after omalizumab injections in a patient with chronic spontaneous urticaria. Clin Exp Dermatol. 2018;43(7):825.
Wiens A, Borda H, Leonart L, et al. Treatment interruption of biological drugs and tofacitinib in rheumatoid arthritis: a systematic review of case reports. Braz J Pharm Sci. 2018;54(4):e17437.
Ozbagcivan O, Akarsu S, Ilknur T, Fetil E. Urticaria and angioedema as possible reactions of omalizumab. An Bras Dermatol. 2018;93(2):304-305.
Adamiak T, Stephens M, Werlin SL. Angioedema occurring in pediatric patients with Crohn disease treated with adalimumab. J Pediatr Gastroenterol Nutr. 2010;51(2):223-225.
Mallbris L, von Bergen F, van Hage M, Stahle M. Recurrent angioedema associated with efalizumab. Acta Derm Venereol. 2009;89(6):665-666.
Worsnop F, Wee J, Natkunarajah J, Moosa Y, Marsden R. Reaction to biological drugs: infliximab for the treatment of toxic epidermal necrolysis subsequently triggering erosive lichen planus. Clin Exp Dermatol. 2012;37(8):879-881.
Allegra A, Oteri G, Alonci A, et al. Association of osteonecrosis of the jaws and POEMS syndrome in a patient assuming rituximab. J Craniomaxillofac Surg. 2014;42(4):279-282.
Ebker T, Rech J, von Wilmowsky C, Neukam FW, Stockmann P. Fulminant course of osteonecrosis of the jaw in a rheumatoid arthritis patient following oral bisphosphonate intake and biologic therapy. Rheumatology (Oxford). 2013;52(1):218-220.
Favia G, Tempesta A, Limongelli L, et al. A case of osteonecrosis of the jaw in a patient with Crohn's disease treated with infliximab. Am J Case Rep. 2017;18:1351-1356.
Assante LR, Barra E, Bocchino M, Zuccarini G, Ferrara G, Sanduzzi A. Tuberculosis of the tongue in a patient with rheumatoid arthritis treated with methotrexate and adalimumab. Infez Med. 2014;22(2):144-148.
Chandrashekara S, Shobha V, Rao V, et al. Incidence of infection other than tuberculosis in patients with autoimmune rheumatic diseases treated with bDMARDs: a real-time clinical experience from India. Rheumatol Int. 2019;39(3):497-507.
Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. 2005;52(11):3403-3412.
Helou E, Grant M, Landry M, Wu X, Morrow JS, Malinis MF. Fatal case of cutaneous-sparing zoster in a renal transplant recipient. Transpl Infect Dis. 2017;19(4):e12704.
Beattie A, Stassen LF, Ekanayake K. Oral squamous cell carcinoma presenting in a patient receiving adalimumab for rheumatoid arthritis. J Oral Maxillofac Surg. 2015;73(11):2136-2141.
Rahman N, Healy C, Flint SR, Stassen LF. Cautionary note: a possible association between oral squamous cell carcinoma and tumor necrosis factor antagonists; need for oral screening. J Clin Rheumatol. 2010;16(4):197-199.
Leao JC, Duarte A, Gueiros LAM, et al. Severe oral epithelial dysplasia in a patient receiving adalimumab therapy. J Oral Pathol Med. 2005;34(7):447-448.
Samimi M, Lauferon F, Huttenberger B, Vaillant L, Goupille P, Machet L. Persistent aphthous mouth ulcers associated with tocilizumab: two cases. Ann Dermatol Venereol. 2013;140(2):120-124.
Geogakopoulou EA, Achtari MD, Evangelou K, Kittas C. Oral non-Hodgkin's lymphoma in a patient with rheumatoid arthritis treated with etanercept and methotrexate. J Clin Exp Dent. 2015;7(1):e180-e182.
Mir-Bonafe JM, Fernandez-Lopez E, Canueto J, Gil-Melcon M, Garcia-Dominguez R, de Unamuno-Perez P. Infliximab-related malignant melanoma and cranial nerves IX and XII palsy secondary to IFN-alpha2b therapy. Int J Dermatol. 2013;52(12):1613-1615.
Collet S, Rombaux P, Rahier JF. Salt ageusia in a patient with Crohn's disease treated with tumor necrosis factor antagonists. Inflamm Bowel Dis. 2013;19(5):e73-e74.
Pers JO, Saraux A, Pierre R, Youinou P. Anti-TNF-alpha immunotherapy is associated with increased gingival inflammation without clinical attachment loss in subjects with rheumatoid arthritis. J Periodontol. 2008;79(9):1645-1651.
Tosios KI, Kalogirou EM, Sklavounou A. Drug-associated hyperpigmentation of the oral mucosa: report of four cases. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018;125(3):e54-e66.
Gaudio A, Corrado A, Santoro N, Maruotti N, Cantatore FP. Melkersson-Rosenthal syndrome in a patient with psoriatic arthritis receiving etanercept. Int J Immunopathol Pharmacol. 2013;26(1):229-233.
Bajpayee L, Berman JS, Govender P, Hawkins FJ. A case of neurologic and parotid sarcoidosis after treatment with tumor necrosis factor alpha (TNF-alpha) inhibitor infliximab. Am J Respir Crit Care Med. 2018;197:A6477.
Grimaux X, Leducq S, Goupille P, Aubourg A, Miquelestorena-Standley E, Samimi M. Aphthous mouth ulcers as an initial manifestation of secukinumab-induced inflammatory bowel disease. Ann Dermatol Venereol. 2018;145(11):676-682.
Ito S, Kato Y, Wakimoto H, et al. Paradoxical adverse events in the oral cavity caused by anti-tumor necrosis factor-α therapy for pustulotic arthro-osteitis. J Dermatol. 2020;47(9):e317-e319.
Kent D, Rickwood S, Di Biase S. Disruption and Maturity: The Next Phase of Biologics. Quintile IMS; 2017 Accessed April 28, 2022. https://www.iqvia.com/-/media/iqvia/pdfs/nemea/uk/disruption_and_maturity_the_next_phase_of_biologics.pdf
Cosentyx (secukinumab) [package insert]. East Hanover, NJ: Novartis Pharmaceutical Corporation; 2016.
Actemra (tocilizumab) [package insert]. San Francisco, CA: Genentech, Inc; 2017.
Rituxan (rituximab) [package insert]. San Francisco, CA: Genentech, Inc; 2010.
Simponi (golimumab) [package insert]. Horsham, PA: Janssen Biotech, Inc; 2011.